紫杉醇脂质体与多西他赛治疗胸腺瘤伴重症肌无力的疗效研究

Comparison of therapeutic effecs of paclitaxel liposome and docetaxel in treatment of thymoma complicated by myasthenia gravis

目的探讨紫杉醇脂质体与多西他赛治疗胸腺瘤合并重症肌无力(MG)疗效比较。方法住院治疗且明确诊断为胸腺瘤术后复发转移合并重症肌无力62例患者。随机分为多西他赛组(n=32)和紫杉醇脂质体组(n=30)。观察2组治疗前后的评氏临床临床绝对评分(clinic definitely score,CDS);乙酰胆碱受体抗体(acetylcholine receptor,AchR-Ab)和胸腺瘤的变化;化疗不良反应。结果 2组治疗后CDS、AchR-Ab均较治疗前显著降低(P<0.05)。2组治疗后CDS、疗效、AchR-Ab水平差异均无统计学意义(P>0.05);2组胸腺瘤治疗疗效差异无统计学意义(P>0.05)。单用多西他赛组副作用与紫杉醇脂质体组差异无统计学意义(P>0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论紫杉醇脂质体治疗胸腺瘤合并MG患者的MG有明显改善、与单药多西他赛疗效相当,对复发转移胸腺瘤与多西他赛一样无明显疗效,可根据临床患者实际情况,进行选择应用。

Objective To investigate and compare the therapeutic effecs of paclitaxel liposome and docetaxel in treatment of thymoma complicated by myasthenia gravis.. Methods A total of 62 patients with thymomas complicated by myasthenia gravis who were treated in our hospital from January 2010 to January 2017 were randomly divided into docetaxel group（n = 32） and paclitaxel liposome group（n = 30）. After treatment the clinic definitely score（CDS）,the changes of acetylcholine receptor（AchR-Ab） and thymomas as well as the adverse effects of chemotherapy were observed and compared between two groups. Results After treatment,the CDS,AchR-Ab levels were significantly decreased in both groups,as compared with those before treatment（P〈0. 05）. However there were no significant differences in CDS,therapeutic effects,AchR-Ab levels,adverse reactions between two groups（P〈0. 05）. Conclusion Paclitaxel liposomes in treatment of thymoma complicated by myasthenia gravis can significantly improve cilinical symptoms of patients,and the therapeutic effects of paclitaxel liposomes are the same as those by single docetaxel,however,both of them have no significant therapeutic effects on recurrence and metastasis of thymoma.